Earnings | Chemcrux Enterprises Limited (BSE: 540395): Q4FY23 Results Out; Total Income fell 26% YoY.

Chemcrux Enterprises Limited, incorporated in April 1996, is a company engaged in the manufacturing of bulk drug intermediates. Their product range includes Para Chloro Benzoic, Ortho Benzoic Acid, and Lasamide, among others. With a focus on the pharmaceutical industry, Chemcrux Enterprises plays a crucial role in supplying essential intermediates used in the production of various drugs. By ensuring the quality and reliability of their products, the company contributes to the overall pharmaceutical supply chain. With their expertise in bulk drug intermediates, Chemcrux Enterprises serves as a trusted partner for pharmaceutical manufacturers, supporting the development and production of vital medications.
• Chemcrux Enterprises Limited reported Total Income for Q4 FY23 of ₹20 Crore down from ₹27 Crore year on year, a negative growth of 26%.
• Total Expenses for Q4 FY23 of ₹16 Crore down from ₹21 Crore year on year, a negative growth of 24%.
• Consolidated Net Profit of ₹3 Crore, down 33% from ₹4.5 Crore in the same quarter of the previous year.
• The Earnings per Share is ₹1.97, down 35% from ₹3.06 in the same quarter of the previous year.